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Feline Hypertrophic Cardiomyopathy: A Spontaneous Large 
Animal Model of Human HCM
Lisa M. Freemana, d, John E. Rusha, Joshua A. Sternb, Gordon S. Hugginsc, 
 Martin S. Maronc
Abstract
Hypertrophic cardiomyopathy (HCM) is a common disease in pet 
cats, affecting 10-15% of the pet cat population. The similarity to hu-
man HCM, the rapid progression of disease, and the defined and read-
ily determined endpoints of feline HCM make it an excellent natu-
ral model that is genotypically and phenotypically similar to human 
HCM. The Maine Coon and Ragdoll cats are particularly valuable 
models of HCM because of myosin binding protein-C mutations and 
even higher disease incidence compared to the overall feline popu-
lation. The cat overcomes many of the limitations of rodent HCM 
models, and can provide enhanced translation of information from 
in vitro and induced small animal models to human clinical trials. 
Physicians and veterinarians working together in a collaborative and 
interdisciplinary approach can accelerate the discovery of more ef-
fective treatments for this and other cardiovascular diseases affecting 
human and veterinary patients.
Keywords: Hypertrophic cardiomyopathy; Cats; Congestive heart 
failure; Natural animal model; Arterial thromboembolism
Introduction
Companion animals and humans frequently suffer from similar 
diseases, such as heart disease, cancer, kidney disease, arthritis, 
diabetes, and obesity. Prevalence rates can be remarkably simi-
lar across species. Obesity, for example, affects similar num-
bers of humans, dogs, and cats. However, because of selective 
breeding to achieve certain physical or behavioral traits, pet 
dogs and cats can have even higher risk for some diseases. For 
example, > 50% of Doberman Pinscher dogs develop dilated 
cardiomyopathy (DCM) [1] and nearly 100% of Cavalier King 
Charles Spaniels develop degenerative mitral valve disease 
(DMVD) [2]. These naturally occurring diseases in pets are 
much more representative of the human disease than induced 
rodent models, so studying the disease in companion animals 
provides an innovative and effective approach for accelerating 
translational research that can ultimately benefit both humans 
and animals. Diagnosis and treatment of companion animal 
diseases can be nearly identical to that of humans, with simi-
lar diagnostic tests (e.g., advanced imaging, laboratory test-
ing, and genetic testing) and treatments (e.g., medications, 
interventional cardiology techniques, and specialized surgical 
techniques). These studies of naturally occurring diseases can 
be conducted in genetically defined colonies or through clini-
cal trials in pet dogs and cats. Both approaches can provide an 
important stepping stone between basic science research and 
human clinical trials that can reduce the all-too-common trans-
lational failures.
Heart Disease Affects More Than Humans
Heart disease is one of the most common diseases of pet dogs 
and cats, affecting 10-15% of all dogs and cats [3, 4]. The most 
common diseases in dogs are DMVD and cardiomyopathies 
(primarily DCM or arrhythmogenic right ventricular cardio-
myopathy), but they also can be affected by a variety of con-
genital heart defects and pericardial diseases. Prevalence rates 
are even higher in certain breeds, with distinct breed predispo-
sitions for heart diseases in both dogs and cats. For example, 
large and giant breed dogs, such as Doberman Pinschers, Great 
Danes, and Irish Wolfhounds, are at higher risk for DCM, 
while small- to medium-size breeds, such as Cavalier King 
Charles Spaniels, Dachshunds, and Poodles are predisposed 
to DMVD. Cats are most commonly affected by hypertrophic 
cardiomyopathy (HCM), with a prevalence of 10-15% in the 
general pet cat population [4]. However, breeds such as the 
Maine Coon cat, Persian, Ragdoll, and Sphynx are at higher 
risk. Similar to humans, sarcomeric protein mutations are im-
plicated in the pathogenesis of feline HCM.
Although heart disease is common in dogs and cats, ath-
erosclerosis is notably absent. This is related, at least in part, to 
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the fact that these species have high high-density lipoprotein 
concentrations.
HCM: Challenges and Solutions
In humans, there are now known to be > 1,500 causative mu-
tations associated with HCM, with the vast majority being 
identified in one of 11 sarcomeric genes. Nonetheless, up to 
30% of human patients with HCM have no identified muta-
tion and there is wide phenotypic variation, even among pa-
tients with the same genetic mutation. Rodent models of HCM 
(e.g., transgenic or naturally occurring mutations) are useful in 
the study of basic mechanisms, but have many limitations for 
translational breakthroughs. While rodent models may have 
the same genetic mutation as in human HCM, the phenotype is 
typically not the same as in human HCM. For example, most 
mouse models expressing myosin binding protein-C (MYB-
PC) mutations do not develop myocardial hypertrophy, the de-
fining trait in humans (and cats) with HCM, or share features 
of symptoms, clinical course, or response to treatment. These 
partial models therefore may have limited predictive value in 
translating information to humans due to species differences 
(e.g., anatomy, metabolic rate, lifespan, and response to treat-
ment). These limitations can result in translational failures 
when drugs showing promise in rodent models are tested in 
human clinical trials. This underscores the importance of hav-
ing relevant preclinical models that can fill the gap between 
induced rodent models and human clinical medicine.
HCM occurs spontaneously and frequently in pet cats, and 
the feline disease is remarkably similar to the human disease 
[5, 6]. There is a male predisposition for HCM in both species 
and clinical signs are similar, although more common and more 
severe in cats than in humans. The most common presentations 
in cats are sudden death or syncope, congestive heart failure 
(CHF), and arterial thromboembolism (ATE). Many cats with 
HCM are identified incidentally when a cardiac murmur is aus-
cultated. Once diagnosed with HCM, most cats eventually die 
from CHF, sudden death, or ATE, while a smaller proportion 
remains subclinical. The same diagnostic tests used in humans 
(e.g., N-terminal B-type natriuretic peptide, radiography, elec-
trocardiography, and echocardiography) are used to diagnose 
cats with HCM (Fig. 1), and similar medications are used to 
manage the disease. Finally, feline HCM is very similar to 
human HCM grossly (Fig. 2) and on histopathology [6]. One 
difference is that feline HCM is a more severe and quickly 
progressive disease than in humans, an advantage when study-
ing outcomes. Clinical studies have shown a median survival 
time in cats with HCM ranging from 92 to 2,153 days, depend-
ing on the predominant clinical signs of the population studied 
(i.e., asymptomatic vs. CHF vs. ATE) [7-9]. Reported median 
survival times for cats with HCM and CHF, for example, range 
from only 92 to 563 days [7-9].
Treatment of Feline HCM
Treatment of feline HCM can be divided into the preclinical 
and clinical (CHF or ATE) time periods. As in humans, despite 
advances in the understanding of HCM, no preclinical therapy 
has demonstrated the ability to slow disease progression or 
reduce ventricular hypertrophy in cats. The most commonly 
employed therapies include cardioprotective strategies such 
as beta-blockade (especially when left ventricular outflow 
Figure 1. A right parasternal echocardiogram with color flow Doppler from a 7-year-old cat with hypertrophic obstructive cardio-
myopathy. Mitral regurgitation and left ventricular outflow tract obstruction secondary to systolic anterior motion of the mitral valve 
are seen. This patient has significant left ventricular hypertrophy of the interventricular septum and free wall.
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tract obstruction is observed), ACE-inhibition, and antiplate-
let drugs. Some promise with novel, targeted therapies is on 
the horizon as sarcomeric modulating drugs are being investi-
gated. The feline HCM model has already served as a bridge 
between research in rodents and human clinical trials with one 
such novel drug trial in cats with HCM [10]. Beta receptor and 
ACE gene polymorphisms are described in cats and their role 
in the response to therapy and progression of HCM, and pro-
vide another opportunity for interdisciplinary research.
In cats with HCM and CHF, the above-mentioned treat-
ments are expanded to include diuretics, such as furosemide, 
and sometimes pimobendan, a drug with positive inotropic and 
vasodilatory effects. ATE is common in cats with HCM, but 
therapy and prognosis for feline patients with ATE are limited 
and represent another area of future research.
Genetics of Feline HCM
Two separate MYBPC mutations, which represent the second 
most common human gene affected, have been identified in 
two cat breeds, the Maine Coon cat and the Ragdoll [11]. In 
Maine Coon cats, for example, an MYBPC mutation (A31P) 
has been detected in approximately 22-42% of Maine Coon 
cats, while a separate MYBPC mutation (R820W) has been 
identified in 27% of Ragdoll cats [11]. The R820W mutation 
was later identified in a human family with HCM and thus 
represents a shared genetic etiology between cats and humans 
[12]. But Maine Coon cats without the A31P mutation also can 
develop HCM, underscoring the presence of unidentified mu-
tations. In these cats and in the majority of cats with HCM, no 
genetic etiology has been identified.
Mutations in humans may be pathogenic or non-pathogen-
ic. And similar to humans, the mutations identified in cats ap-
pear to have incomplete penetrance. In Maine Coon cats with a 
MYBPC mutation, penetrance is reported to be 6-8% in A31P 
heterozygotes and 58-80% in homozygotes [11]. However, 
in both humans and cats, some patients with mutations have 
minimal cardiac changes, while some with the same mutation 
and even in the same family have severe hypertrophy with ad-
vanced clinical signs or sudden death. This variable genotype-
phenotype relationship suggests that there are other genetic or 
environmental modifiers of phenotype.
Nutrient-gene interactions (nutrigenomics) may provide 
a key to understanding of the phenotypic variability of HCM 
and an opportunity for improved therapeutic targets and nu-
tritional strategies to reduce morbidity and mortality. Pet cats 
with HCM are larger in size, more likely to be overweight, 
have higher concentrations of glucose and IGF-1, and grow 
more quickly in early life compared to healthy controls [13]. 
This suggests that early growth and nutrition may influence the 
development and course of HCM in genetically predisposed 
cats. Studying the role of nutrigenomics in humans with HCM 
is warranted.
Opportunities for Collaboration
Instead of approaching HCM from the traditional silos of in-
dividual disciplines, a collaborative and interdisciplinary ap-
proach can accelerate translation of research into effective 
medical innovations for humans with this disease. Studying 
HCM in cats with naturally occurring disease can enhance 
translational efficiency and effectiveness between basic sci-
ence research and human clinical trials. At the same time, dis-
coveries in humans can spur advances in the treatment of cats 
with this disease.
Cats with HCM could serve as a good model for human 
HCM to study novel drugs, disease progression, or develop-
ment of CHF, but would be less than ideal for studying sud-
den death, since this is not a common occurrence in cats with 
HCM. Veterinary cardiologists can help to determine the opti-
mal study design based on the research question and outcomes 
of interest. Some specific opportunities to collaborate or learn 
more are listed below. 1) Feline HCM can be studied as a 
model for human HCM either as genetically defined cats in 
a colony or through clinical trials in pet cats (which typically 
are not screened for mutations unless they are of certain spe-
cific breeds, such as the Maine Coon cat or Ragdoll). 2) Find 
out about current clinical trials in companion animals. Animal 
clinical trials can be shorter and less expensive since dogs and 
cats with heart disease often reach endpoints (e.g., heart fail-
ure) earlier than humans. There are numerous, ongoing clinical 
trials in a variety of naturally occurring diseases in companion 
animals, including HCM. Clinical trials in companion animals 
must undergo approval (by an Institutional Animal Care and 
Use Committee or similar body) and pet owners must sign 
an informed consent form before volunteering to enroll their 
pets, along with a variety of other safeguards for both the pet 
owner and the pet. A list of some of the current clinical trials 
across the United States can be found on the American Vet-
erinary Medical Association’s Clinical Trials Registry (https://
ebusiness.avma.org/aahsd/study_search.aspx) and on indi-
Figure 2. A gross pathology specimen from a 5-year-old cat with hyper-
trophic cardiomyopathy. The heart is shown in a transverse plane at the 
level of the papillary muscles in the left ventricle. Severe concentric left 
ventricular hypertrophy is evident with dramatic reduction in the size of 
the left ventricular lumen.
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vidual veterinary school website’s (e.g., http://vet.tufts.edu/
cvmc/clinical-studies/, http://www.vetmed.ucdavis.edu/clini-
caltrials/current_trials/index.cfm). 3) Read about published 
research using natural animal models of HCM and other car-
diovascular diseases. Many veterinary studies are indexed in 
Medline and can be accessed via Pubmed or Ovid. However, 
some veterinary studies may only be indexed in CAB Ab-
stracts. Therefore, one must deliberately seek out studies us-
ing natural animal models. 4) Invite veterinary cardiologists 
to give sessions at cardiology meetings. The interactions can 
be enlightening, both from a clinical and research perspective. 
5) Collaborate with veterinarians and veterinary cardiologists 
in research. An interdisciplinary approach provides impor-
tant advantages for optimal study design. Despite the many 
similarities between human and feline HCM, there are some 
important metabolic, nutritional, and anatomic differences 
across species that are important to understand. 6) Reach out 
to a veterinary cardiologist to learn more. There are currently 
> 300 board-certified veterinary cardiologists in the United 
States (and > 500 worldwide). Cardiologists are located at all 
30 of the United States veterinary schools and in many private 
specialty practices across the country. Listings of board-certi-
fied veterinary cardiologists can be found online (http://find.
vetspecialists.com).
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